National Institute for Public Health, Unit Vaccinology, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands.
Vaccine. 2011 Apr 18;29(18):3390-7. doi: 10.1016/j.vaccine.2011.02.085. Epub 2011 Mar 11.
GMP-batches of Sabin-IPV were characterized for their antigenic and immunogenic properties. Antigenic fingerprints of Sabin-IPV reveal that the D-antigen unit is not a fixed amount of antigen but depends on antibody and assay type. Instead of the D-antigen unit we propose standardization of IPV based on a combination of protein amount for dose and D-antigenicity for quality of the vaccine. Although Sabin-IPV type 2 is less immunogenic than regular wild type IPV type 2, the immunogenicity (virus neutralizing titers) per microgram antigen for Sabin-IPV type 2 is in the same order as for wild type serotypes 1 and 3. The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary.
Sabin-IPV 的 GMP 批次的抗原性和免疫原性特征。Sabin-IPV 的抗原指纹图谱表明,D 抗原单位不是固定的抗原量,而是取决于抗体和检测类型。我们建议,不使用 D 抗原单位,而是基于疫苗剂量的蛋白质含量和 D 抗原性来对 IPV 进行标准化。尽管 Sabin-IPV 型 2 的免疫原性不如常规野生型 IPV 型 2,但每微克抗原的免疫原性(病毒中和滴度)对于 Sabin-IPV 型 2 与野生型血清型 1 和 3 相当。后一种观察结果与人体试验数据一致。这表明,为了弥补 Sabin-IPV 型 2 较低的大鼠免疫原性,可能不需要更高剂量的 Sabin-IPV 型 2。